IMG_0594
April 13-14, 2022 | Washington, DC USA
Shadow

WELCOME

Arrowhead Publishers is pleased to announce the return of the 7th Annual Translational Microbiome Conference – live and in-person, on April 13-14, 2022 in Washington DC. The Translational Microbiome Conference was the first microbiome conference in the field to focus exclusively on the hurdles and challenges to commercial success in the space and continues to expand on that mission yearly, bringing well considered and curated content to a diverse audience at an affordable price.

CONFERENCE FOCUS

Entering its 7th year in 2022, the meeting will continue to focus and build on the challenges and hurdles that companies working in the microbiome space will have to recognize and navigate in order to successfully commercialize their products. With a broad focus spanning multiple disease states (oncology, dermatology, inflammatory disorders, among others) attendees will have the opportunity to hear the leading companies discuss the work they have underway and how they are meeting these challenges head-on to apply recent discoveries to a variety of disease processes, restoration of health and improved outcomes.

FEATURED SPEAKERS

Why You Should Attend

Partnering Software & Meetings

Easily schedule meetings with our partnering system in order to maximize your time at the event. Schedule one-to-one meetings in advance and stay connected after the event.

Industry-Leading Speaking Faculty

Our tightly curated content provides tangible and useful insights to how your peers are addressing their scientific, clinical and commercial approach to the space.

Network With Industry Colleagues

One-to-One meeting space, breakfasts, extended breaks, luncheons and receptions provide attendees with multiple opportunities to connect with colleagues in the space.

20+ Exhibitors/Service Providers

Meet with and/or re-connect with exhibitors and service providers and learn about the latest tools and resources driving the field of microbiome science.

THIS YEAR'S EXHIBITORS AND SPONSORS

Conference topics will feature speakers and panels on animal models, bioinformatics challenges, intellectual property management, investment deals and approaches, pharma deals in the microbiome space, and the need for standards.

MINNEAPOLIS, November 28, 2017– Arrowhead Publishers unveils a growing roster of speakers for its 4th Annual Translational Microbiome Conference, to take place April 18-20 at Boston Marriott Long Wharf. The conference is designed to connect scientists at the forefront of microbiome research with pioneering companies investing to apply microbiome-based findings to innovate medical solutions. With a broad focus spanning multiple disease states (oncology, dermatology, inflammatory disorders, among others) attendees will have the opportunity to hear leading companies discuss the work they have underway and how they are meeting these challenges head-on to apply recent discoveries to a variety of disease processes, restoration of health, and improved outcomes.

“The topics and speakers for this year’s conference offer real education, insights and benefits our attendees can apply within their own organizations,” said John Waslif, Managing Director of Arrowhead Publishers and Conferences.

Speakers already confirmed for the conference include:
Peter Christey, Ph.D.
Co-Founder and Chief Executive Officer, General Automation Lab Technologies (GALT)
GALT’s innovative high-throughput microbiology platform can isolate multiple species from complex samples, such as soil and stool, allowing researchers to rapidly screen whole populations or engineered libraries. Dr. Christey is leveraging GALT tools to revolutionize how microbial studies are conducted, opening previously unreachable territories for scientists to explore.

Olga Danilchanka, Ph.D.
Microbiome Lead, Exploratory Science Center, Merck
Dr. Danilchanka serves as Microbiome Lead for Merck’s Exploratory Science Center, which focuses on the earliest stages of discovery research to better understand the underlying biology of human disease. Dr. Danilchanka’s team explores the most promising areas of emerging disease biology, including the role of the microbiome in disease, and works to gain new insights to inform Merck’s ongoing drug discovery.

Pinaki Panigrahi, M.D., Ph.D.
Professor, Department of Epidemiology and Pediatrics; Director of Center for Global Health and Development, University of Nebraska Medical Center, College of Public Health
An elected fellow of the Infectious Diseases Society of America, Dr. Panigrahi has studied neonatal and child health issues in developed nations and in the developing world. His expertise spans necrotizing enterocolitis, neonatal infections, diarrhea, malaria, birth asphyxia, prematurity, stillbirths and nutrition.

Mark Smith, Ph.D.,
Chief Executive Officer, Finch Therapeutics
Finch uses machine-learning algorithms informed by high-throughput molecular data to reverse-engineer successful clinical experience with fecal transplantation. Rather than relying on in-vitro screening of a library of microbes, Finch uses this human-first discovery approach to identify strains that drive clinical outcomes and to develop therapies that deliver these microbial communities to patients.

Paul Giannasca, Ph.D.
Global Scientific Lead, GI Health, Nestle Health Science
Dr. Giannasca identifies and manages new nutritional and technological platforms relevant for the Gastrointestinal Health strategy for Nestle Health Science. Dr. Giannasca holds multiple U.S. patents covering active and passive immunization against Clostridium difficile disease and has published more than 25 papers in the areas of infectious diseases, vaccine development, active and passive immunization and vaccine-induced protection.

Other notable speakers participating in the 2018 conference include:
* David Kyle, Ph.D., Chief Scientific Officer, Evolve Biosystems
* Ingmar Claes, Ph.D., Chief Scientific Officer, Yun Probiotherapy
* Veronika Oudova, Chief Executive Officer, S Biomedic
* Travis Whitfill, Co-Founder and Chief Science Officer, Azitra
* Jennifer A. Wargo, M.D., Associate Professor, Department of Surgical Oncology, Division of Surgery, The University of Texas MD Anderson Cancer Center

New additions to the conference this year are topic-focused tracks for nutrition and for skin. A parallel consumer track will again be offered. Each track will be closely focused on key issues in its specific industry and the challenges common to companies trying to enter the microbiome space in that area.

Keynote address for the conference will be delivered by Emeran Mayer, M.D., Ph.D.
Director, UCLA Gail and Gerald Oppenheimer Family Center for Neurobiology of Stress; Professor, Medicine; Professor, Psychiatry and Biobehavioral Sciences; Professor, Digestive Diseases/Gastroenterology; Co-Director, CURE: Digestive Diseases Research Center; Professor, Physiology, UCLA David Geffen School of Medicine
Dr. Mayer has a career-long interest in clinical and research aspects of brain-body interactions, with a focus on brain-gut interactions in health and disease. A widely recognized expert for functional GI disorders, he is also recognized as one of the leading investigators in the world of chronic visceral pain and of the brain-gut axis.

Further information about the 4th Annual Translational Microbiome Conference can be found at www.microbiomeconference.com.

About Us

Our events give attendees a conference experience that encompasses learning, networking and professional growth. We strive to facilitate connections. At our events, attendees, speakers, sponsors and exhibitors have opportunities to network and then to utilize those connections to further their professional goals. At Arrowhead Publishers, our focus is on bringing life sciences industry professionals together to help move research forward. Learn more about us at www.arrowheadpublishers.com.

Contact Us

Arrowhead Publishers & Conferences
PO Box 96
7730 Laredo Drive, #96
Chanhassen, MN 55317
866-945-0263
enquiries@arrowheadpublishers.com

PRIVACY POLICY

Organized By

Join Our Linked In Group & Twitter Feed